LYEL VS WVE Stock Comparison
Performance
LYEL10/100
10/100
LYEL returned -58.96% in the last 12 months. Based on SPY's performance of -13.12%, its performance is below average giving it a score of 10 of 100.
WVE100/100
100/100
WVE returned 57.68% in the last 12 months. Based on SPY's performance of 9.73%, its performance is above average giving it a score of 100 of 100.
Technicals
LYEL54/100
54/100
LYEL receives a 53 of 100 based on 14 indicators. 7 are bullish, 6 are bearish.
WVE79/100
79/100
WVE receives a 78 of 100 based on 14 indicators. 10 are bullish, 2 are bearish.
Earnings
LYEL100/100
100/100
LYEL has missed earnings 1 times in the last 20 quarters.
WVE10/100
10/100
WVE has missed earnings 14 times in the last 20 quarters.
Profit
LYEL10/100
10/100
Out of the last 15 quarters, LYEL has had 0 profitable quarters and has increased their profits year over year on 0 of them.
WVE10/100
10/100
Out of the last 20 quarters, WVE has had 1 profitable quarters and has increased their profits year over year on 1 of them.
Volatility
LYEL43/100
43/100
LYEL has had a lower than average amount of volatility over the last 12 months giving it a score of 43 of 100.
WVE51/100
51/100
WVE has had a higher than average amount of volatility over the last 12 months giving it a score of 50 of 100.
Analyst Price Targets
LYEL
"Analyst Price Targets" not found for LYEL
WVE83/100
83/100
6 analysts offer 12-month price targets for WVE. Together, they have an average target of 0, the most optimistic target put WVE at 0 within 12-months and the most pessimistic has WVE at 0.
Sentiment
LYEL
"Sentiment" not found for LYEL
WVE69/100
69/100
WVE had a bullish sentiment score of 69.37% across Twitter and StockTwits over the last 12 months. It had an average of 2.25 posts, 0.00 comments, and 0.12 likes per day.
All score calculations are broken down here to help you make more informed investing decisions
Lyell Immunopharma, Inc. Common Stock Summary
Nasdaq / LYEL
Healthcare
Biotechnology
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Wave Life Sciences Ltd. Ordinary Shares Summary
Nasdaq / WVE
Healthcare
Biotechnology
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional proteins, or modulate protein expression. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington's disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; and ATXN3, a discovery stage program for the treatment of spinocerebellar ataxia 3, as well as multiple preclinical programs for CNS disorders. In addition, it focuses on developing GalNAc-conjugated AIMers to treat hepatic indications comprising Alpha-1 antitrypsin deficiency (AATD); and two preclinical programs, such as Usher syndrome type 2A (USH2A) and retinitis pigmentosa due to a P23H mutation in the RHO gene (RhoP23H) for the treatment of retinal diseases. It has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, University of Oxford, University of Massachusetts, Western Washington University, Grenoble Institute of Neurosciences, IRBM S.p.A, University of Louisville, and University College London. The company was incorporated in 2012 and is based in Singapore.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare LYEL to other companies in the same or a similar industry.